Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study
In Chinese patients with relapsed or refractory multiple myeloma who have undergone one to three prior therapies, progression-free and overall survival were significantly improved with ixazomib plus lenalidomide/dexamethasone (Rd) versus placebo plus Rd, with limited additional toxicity. These findings from the China Continuation study were published by Jian Hou, MD, of the Chang Zheng Hospital, Shanghai, China, and colleagues in the Journal of Hematology and Oncology.
The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study, which included just six Chinese patients. In the expansion study, 57 patients were randomized to receive ixazomib-Rd, and 58 received placebo-Rd.
At data cutoff, there was a significant 67% improvement in the primary endpoint of progression-free survival with ixazomib-Rd compared with placebo-Rd (median 6.7 vs. 4.0 months). Ixazomib-Rd also resulted in a significant improvement in overall survival versus placebo-Rd (median 25.8 vs. 15.8 months), after a median follow-up of about 20 months.
According to the investigators: “These findings support the efficacy and tolerability of this all-oral triplet regimen as a treatment option for patients with relapsed/refractory multiple myeloma around the world.”